Skip to main content

Currently Skimming:

5 Lessons Learned from Coordinated Research in Other Fields
Pages 59-66

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 59...
... fields that can help the radiation research community draw lessons to be learned for organizing a cohesive low dose radiation research program. Four different approaches in two research fields -- air pollution and genomic studies -- were described in some detail at the symposium.
From page 60...
... presenting on models for funding research in health effects of air pollution. Seated at the table from left to right are Dr.
From page 61...
... Funding for PM research continues today within EPA's Air, Climate, ­ and Energy Research Program and was approximately $95 million in fiscal year 2019. 5.1.2 The Health Effects Institute HEI is an independent, nonprofit corporation specializing in research on the health effects of air pollution.
From page 62...
... It also periodically performs scientific reviews; currently HEI is undertaking a systematic review of the literature on the health effects of exposure to traffic. HEI-funded results are publicly available.2 Mr.
From page 63...
... described two large-scale biology initiatives and discussed the relevance of several lessons learned for setting up a low dose radiation research program in the United States. 5.2.1 The Cancer Genome Atlas (TCGA)
From page 64...
... She said that to successfully complete the project there was a need to • Organize the functions of the project into an integrated whole; • Obtain high-quality biosamples (which turned out to be a major challenge) ; • Integrate different disciplines and technologies into functional teams and results; • Transition from existing sequencing technologies to more sophisti cated approaches; • Build a new generation of analysis teams to carry out the project; • Resolve policy issues related to data access and informed consent; and • Communicate about TCGA to the cancer research community and provide opportunities for comments, input, or questions.
From page 65...
... Through its efforts, the I-SPY 2 team has also produced sufficient data to establish a surrogate endpoint, pathologic complete response, which was approved by FDA in 2014 for use in breast cancer clinical trials.


This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.